This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M07.3 | Special Copayment Reduction: V237 (severe intractable disease, 5 years) |
| B. Synonyms | Psoriatic arthritis, psoriatic arthropathy |
| C. Adult onset | Adult onset: very high — psoriatic arthropathy occurs in about 20-30% of psoriasis patients; manifests mainly in adults (30s-50s). |
| 1. History | See main text |
| 2. Causes | See main text |
| 3. Genetics | See main text |
| 4. General epidemiology | See main text |
| 5. Pathophysiology | See main text |
| 6. Symptoms | See main text |
| 7. Signs | See main text |
| 8. Screening | See main text |
| 9. Diagnosis | See main text |
| 10. Treatment | See main text |
| 11. Prognosis | See main text |
| 12. Prevention | See main text |
| 13. References | See main text |
The history of psoriatic arthritis (PsA) began in 1818 when the French physician Jean-Louis Alibert first described joint involvement in patients with psoriasis. However, psoriatic arthritis was established as a distinct clinical entity separate from rheumatoid arthritis in 1964, when Bernard Blumberg and Hollander reported that rheumatoid factor was negative in the joint fluid of psoriasis patients. In 1973, Wright and Moll described five clinical subtypes of psoriatic arthritis (asymmetric small joint arthritis, distal interphalangeal joint arthritis, rheumatoid arthritis-like form, spondylitis form, and arthritis mutilans).
In 2006, the CASPAR (ClASsification criteria for Psoriatic ARthritis) classification criteria for psoriatic arthritis were published, greatly improving diagnostic accuracy. With the introduction of biologics (anti-TNF, anti-IL-17, anti-IL-23), treatment outcomes of PsA improved greatly, and since the 2010s JAK inhibitors (tofacitinib, upadacitinib) and a PDE4 inhibitor (apremilast) have been additionally approved.
M07.3 (other psoriatic arthropathies) is the code classifying psoriatic arthropathies other than arthritis mutilans (M07.1) and psoriatic spondylitis (M07.2). In clinical practice most psoriatic arthropathy patients are classified as M07.3, including asymmetric small-joint arthritis, distal interphalangeal joint arthritis, symmetric polyarthritis resembling rheumatoid arthritis, dactylitis, and enthesitis.
The cause of psoriatic arthritis is a combined action of genetic predisposition, environmental factors, and immunological abnormalities. HLA-B27 has a high positivity rate in the spondylitis form (about 50-60%), and HLA-B38, HLA-B39, HLA-Cw6, and others are also associated. In GWAS, IL-12B, IL-23R, TNFAIP3, TRAF3IP2, and others are associated with PsA susceptibility. Skin and joint trauma (the joint analogue of the Koebner phenomenon), streptococcal infection, smoking, and obesity are triggering factors. The IL-23/Th17 axis, TNF-α, and IL-17A/F are the main inflammatory cytokines.
The strongest genetic association in psoriatic arthritis is in the HLA region. HLA-Cw6 (PSORS1) is closely associated with psoriatic skin lesions, and HLA-B27 is associated with the spondyloarthritis phenotype (spondylitis, sacroiliitis). In GWAS, IL-12B (p40 subunit), IL-23R (R381Q variant), TRAF3IP2 (ACT1), TNFAIP3 (A20), RUNX3, TYK2, and others have been identified as psoriatic arthritis susceptibility genes. The IL-23R variant provides a biological basis explaining the high efficacy of anti-IL-23 biologics.
Psoriatic arthritis occurs in about 20-30% of patients with psoriasis. The overall prevalence is about 0.1-0.25% of the general population and is estimated at about 0.1% in Korea. Arthritis develops on average 10-15 years after the diagnosis of psoriasis, but in some patients arthritis appears before psoriasis. The incidence in men and women is nearly equal. The median age at diagnosis is in the 30s to 50s.
The pathophysiology of psoriatic arthritis centers on the IL-23/Th17 axis. Plasmacytoid dendritic cells (pDC) and dendritic cells in the skin produce IL-23, which activates Th17 cells and ILC3, and IL-17A, IL-17F, and IL-22 are secreted. In the joints, secretion of IL-17 and IL-22 by tissue-resident memory T cells (T_RM) promotes synovial inflammation. TNF-α, IL-6, and IL-1β also contribute to joint destruction. Bone erosion progresses through osteoclast activation caused by RANKL overexpression. On the other hand, new bone formation (periosteal new bone formation) is also a feature of PsA, and the dual 'destructive and constructive' presentation, in which joint ankylosis and bone proliferation appear simultaneously, is specific.
Asymmetric small-joint arthritis: asymmetric swelling and pain of 1-4 small joints of the fingers and toes. Distal interphalangeal (DIP) arthritis: involvement of the DIP joints of the hands and feet, frequently accompanied by nail psoriasis. Symmetric polyarthritis resembling rheumatoid arthritis: RF-negative, symmetric polyarticular involvement similar to RA, with DIP involvement, nail changes, and psoriasis as distinguishing points. Dactylitis: "sausage finger/toe" (swelling of the entire finger or toe). Enthesitis: pain at the insertions of the Achilles tendon, plantar fascia, and patellar tendon. Accompanied by skin psoriasis and nail psoriasis (pitting, onycholysis).
Asymmetric joint swelling and tenderness, dactylitis (sausage fingers/toes), DIP joint involvement, nail psoriasis. CASPAR criteria: psoriasis (current/past history/family history), negative RF, nail psoriasis, dactylitis, radiographic findings (juxtaarticular new bone formation), sum of 5 items ≥3 points. Tests: elevated CRP/ESR, negative RF (usually), joint X-ray (bone erosion, juxtaarticular new bone), MRI/ultrasound (synovial thickening, enthesial inflammation).
In psoriasis patients with joint symptoms (arthralgia, dactylitis, enthesitis, DIP involvement), psoriatic arthritis is screened with the PEST or ToPAS questionnaire. If psoriatic arthritis is suspected, refer to rheumatology. A diagnostic delay of 6 months or more significantly increases radiographic damage.
Diagnosed by the CASPAR criteria. Inflammation is assessed by joint X-ray (juxtaarticular new bone, bone erosion), MRI (bone marrow edema, synovial thickening), and joint ultrasound (power Doppler synovial thickening, enthesial thickening). RF negative; HLA-B27 testing (useful with spinal involvement). Differentiate from RA (RF-positive, symmetric MCP-centered involvement, RA nodules), reactive arthritis (preceding infection, HLAB27), and gout (hyperuricemia, urate crystals).
Mild to moderate: NSAIDs, local injection (intra-articular steroid), csDMARDs (MTX, leflunomide, sulfasalazine). Moderate to severe: biologics (anti-TNF, anti-IL-17, anti-IL-23p19), JAK inhibitors (tofacitinib, upadacitinib), PDE4 inhibitor (apremilast). Treatment of enthesitis and dactylitis: NSAIDs, local steroid injection, anti-TNF, anti-IL-17. Physical therapy: maintaining joint function, managing enthesitis.
With appropriate treatment, psoriatic arthropathy can maintain good joint function and quality of life. However, functional impairment occurs with diagnostic delay, inappropriate treatment, or progression of severe bone erosion. Early use of biologics suppresses radiographic progression. Management of cardiovascular risk factors (hypertension, hyperlipidemia, obesity, diabetes) is important for long-term prognosis.
Early screening for psoriatic arthritis in psoriasis patients and referral to rheumatology are the key to preventing joint damage. Active NSAID and csDMARD treatment suppresses early joint damage. There is evidence that active treatment of skin psoriasis (anti-IL-17, anti-IL-23, dupilumab, etc.) may also lower the risk of developing psoriatic arthropathy. Weight management, smoking cessation, and regular exercise help lower the severity of psoriatic arthropathy.